Find out how minimally invasive thrombectomy procedures can potentially reduce the risk of DVT complications, such as post-thrombotic syndrome (PTS).
DVT blood clots affect up to 900,000 Americans each year1
100,000 people in the U.S. die each year from blood clots2
Up to 50% of people with DVT will develop PTS3
Currently, most patients diagnosed with a DVT blood clot receive anticoagulation and compression stocking therapy to help minimize clot propagation.
Mechanical thrombectomy devices are designed to help break up and physically remove all or portions of the blood clot. These devices are designed to remove extensive clots more efficiently, provide quicker restoration of venous flow and assist in restoring normal venous valve function.
Pharmacomechanical thrombolysis combines thrombolytic therapy with mechanical thrombectomy procedures to remove or dissolve the blood clot. This combination approach is used to maximize the benefits of the two treatments in sub-acute and chronic thrombus, and may decrease the risk of post-thrombotic syndrome.
Mechanical thrombectomy gives appropriate DVT patients a new treatment option and offers them:
Compared to catheter-directed lytic therapy, pharmacomechanical thrombectomy may provide shorter treatment times, lower doses of thrombolytic drugs and fewer complications. This may help reduce ICU and total hospital stays—ultimately reducing overall hospital costs. In addition, pharmacomechanical thrombectomy may help reduce the costs associated with the development of post-thrombotic syndrome, a lifelong debilitating condition. Download the DVT Hospital Economics presentation to see a cost comparison for a variety of DVT treatments.
Sign up to have your practice listed in the doctor finder tool on ClearingTheClot.com, a patient education website for deep vein thrombosis.